Diagnostic value of a urine-based tumor marker for screening lower urinary tract in low-risk patients with asymptomatic microscopic hematuria

Urologia Internationalis

Volumn 87, Issue 1, 2011, Pages 35-41

  Sagnak, Levent ^a,b   Ersoy, Hamit ^a   Gucuk, Osman ^a   Ozok, Ugur ^a   Topaloglu, Hikmet ^a  

^a DISKAPI YILDIRIM BEYAZIT TRAINING AND RESEARCH HOSPITAL   (Turkey)

^b Angoraevleri Altinbel Villalari No: 38/A ^*  (Turkey)

Author keywords

Asymptomatic microscopic hematuria; Low risk patients; NMP22 BladderChek ; Urine cytology

Indexed keywords

TUMOR MARKER;

ADULT; ARTICLE; BLADDER CANCER; CANCER RISK; CYSTOSCOPY; DEVICE; DIAGNOSTIC TEST ACCURACY STUDY; DIAGNOSTIC VALUE; ECHOGRAPHY; FEMALE; HEMATURIA; HUMAN; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SCREENING TEST; SENSITIVITY AND SPECIFICITY; URETHRA; URINARY TRACT BIOPSY; URINE CYTOLOGY;

ADULT; ASYMPTOMATIC DISEASES; BIOPSY; CYSTOSCOPY; FEMALE; HEMATURIA; HUMANS; MALE; NUCLEAR PROTEINS; PATIENT SELECTION; POINT-OF-CARE SYSTEMS; PRACTICE GUIDELINES AS TOPIC; PREDICTIVE VALUE OF TESTS; PROSPECTIVE STUDIES; REAGENT KITS, DIAGNOSTIC; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; TURKEY; URINE; UROLOGIC NEOPLASMS; YOUNG ADULT;

EID: 80051785418     PISSN: 00421138     EISSN: 14230399     Source Type: Journal    
DOI: 10.1159/000325376     Document Type: Article

References (26)

1. Mariani AJ, Mariani MC, Macchioni C, et al: The significance of adult hematuria: 1,000 hematuria evaluations including a risk-benefit and cost-effectiveness analysis. J Urol 1989; 141: 350-355. (Pubitemid 19061317)
2. Sugimura K, Ikemoto S, Kawashima H, et al: Microscopic hematuria as a screening marker for urinary tract malignancies. Int J Urol 2001; 8: 1-5. (Pubitemid 32156106)
3. Mohr DN, Offord KP, Owen RA, Melton LJA: Asymptomatic microhematuria and urologic disease. A population-based study. JAMA 1986; 256: 224-229. (Pubitemid 16097834)
4. Silverman DT, Hartge P, Morrison AS, Devesa SS: Epidemiology of bladder cancer. Hematol Oncol Clin North Am 1992; 6: 1-30.
5. Lotan Y, Elias K, Svatek RS, et al: Bladder cancer screening in a high-risk asymptomatic population using a point-of-care urinebased protein tumor marker. J Urol 2009; 182: 52-58.
6. Jemal A, Siegel R, Ward E: Cancer statistics, 2009. CA Cancer J Clin 2009; 59: 225-249.
7. Chiong E, Gaston KE, Grossman HB: Urinary markers in screening patients with hematuria. World J Urol 2008; 26: 25-30.
8. Van Rhijn BW, van der Poel HG, van der Kwast TH: Urine markers for bladder cancer surveillance: A systematic review. Eur Urol 2005; 47: 736-748. (Pubitemid 40745338)
9. Trivedi D, Messing EM: Commentary: The role of cytologic analysis of voided urine in the work-up of asymptomatic microhematuria. BMC Urol 2009; 9: 13.
10. Villicana P, Whiting B, Goodison S, Rosser CJ: Urine-based assays for the detection of bladder cancer. Biomark Med 2009; 3: 265.
11. Kumar A, Kumar R, Gupta NP: Comparison of NMP22 BladderChekh and urine cytology for the detection of recurrent bladder cancer. Jpn J Clin Oncol 2006; 36: 172-175.
12. US Food and Drug Administration Premarket Approval: PMA Database: PMA 940025 S003. Available at http://www.accessdata. fda.gov/scripts/cdrh/cfdocs/ cfPMA/PMA. cfm?ID=7442 (accessed February 10, 2005).
13. Grossfeld GD, Litwin MS, Wolf JS Jr, et al: Evaluation of asymptomatic microscopic hematuria in adults: The American Urological Association Best Practice Policy, Part II: Patient evaluation, cytology, voided markers, imaging, cystoscopy, nephrology evaluation, and follow-up. Urology 2001; 57: 604-610.
14. Wollin T, Laroche B, Psooy K: Canadian guidelines for the management of asymptomatic microscopic hematuria in adults. Can Urol Assoc J 2009; 3: 77-80.
15. Moonen PMJ, Kiemeney LALM, Witjes JA: Urinary NMP22 BladderChekh test in the diagnosis of superficial bladder cancer. Eur Urol 2005; 48: 951-956. (Pubitemid 41641642)
16. Murphy WM: Current status of urinary cytology in the evaluation of bladder neoplasms. Hum Pathol 1990; 21: 886-896. (Pubitemid 20308410)
17. Wittekind C, Greene FL, Hutter RVP, et al: TNM Atlas, ed 5. Geneva, UICC, 2004.
18. Epstein JI, Amin MB, Reuter VR, Mostofi FK: The World Health Organization/International Society of Urological Pathology consensus classification of urothelial (transitional cell) neoplasms of the urinary bladder. Bladder Consensus Conference Committee. Am J Surg Pathol 1998; 22: 1435-1448. (Pubitemid 28550639)
19. McDonald MM, Swagerty D, Wetzel L: Assessment of microscopic hematuria in adults. Am Fam Physician 2006; 73: 1748-1754.
20. Castro G, Fernandez F, Corriente M: Usefulness of urine cytology in the diagnosis of bladder cancer: Relationship with pathologic findings. Actas Urol Esp 2008; 32: 904-907.
21. Grossman HB, Soloway M, Messing E, et al: Surveillance for recurrent bladder cancer using a point-of-care proteomic assay. JAMA 2006; 295: 299-305. (Pubitemid 43112958)
22. Choi HS, Lee SI, Kim DJ, Jeong TY: Usefulness of the NMP22 BladderChekh test for screening and follow-up of bladder cancer. Korean J Urol 2010; 51: 88-93.
23. Khadra MH, Pickard RS, Charlton M, et al: A prospective analysis of 1,930 patients with hematuria to evaluate current diagnostic practice. J Urol 2000; 163: 524-527. (Pubitemid 30060509)
24. Murakami S, Igarashi T, Hara S, Shimazaki J: Strategies for asymptomatic microscopic hematuria. A prospective study of 1,034 patients. J Urol 1990; 144: 99-101. (Pubitemid 20221283)
25. Hofland CA, Mariani AJ: Is urine cytology required for a hematuria evaluation? J Urol 2004; 171: 324-326. (Pubitemid 37549157)
26. Lotan Y, Roehrborn CG: Sensitivity and specificity of commonly available bladder tumor markers versus cytology: Results of a comprehensive literature review and metaanalysis. Urology 2003; 61: 109-118. (Pubitemid 36151724)